

Syn-One Test[®]

COULD A RELIABLE BIOMARKER HELP YOU UNDERSTAND YOUR PATIENT'S REM SLEEP BEHAVIOR DISORDER?

Patients with REM sleep behavior disorder (RBD) have a high likelihood of converting to a neurodegenerative disease during their lifetimes. A study of 1,280 patients with idiopathic RBD (iRBD) showed a **73.5% conversion to a synucleinopathy**—Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy—within 12 years.¹ Scientific literature concludes that abnormal α -synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades.²


PATHOLOGICAL INSIGHTS BENEATH THE SKIN

Through a simple skin biopsy procedure, the Syn-One Test has been used by 3,000 neurologists and other clinicians to provide visual proof of the phosphorylated form of alpha-synuclein (P-SYN) to support the care of 40,000 patients.

In CND's NIH-sponsored Syn-Sleep Study, the Syn-One Test detected phosphorylated alpha-synuclein in 75% (60/80) of iRBD patients at baseline.³

For clinicians and patients looking for more precise answers related to an RBD diagnosis, the Syn-One Test may be a helpful aid.

- Syn-One uses three (3) skin punch biopsy samples collected in a 15-minute in-office procedure
- CND provides a pathology report with visual evidence of P-SYN deposition (or the absence of P-SYN) along with other markers of peripheral neurodegeneration
- Test results may help rule out the presence of synuclein pathology
- CND offers live clinical consults with a neurologist to discuss pathological findings and facilitates access to resources focused on prodromal synucleinopathies



To learn more about the Syn-One Test contact us at support@cndlifesciences.com

1. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. 2019;142(3):744-759. doi:10.1093/brain/awz030

2. Miglis MG, Adler CH, Antelmi E. Biomarkers of conversion to α -synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. *Lancet Neurol*. 2021 Aug;20(8):671-684. doi: 10.1016/S1474-4422(21)00176-9

3. Based on interim results of CND Life Sciences' NIH-sponsored multicenter, prospective, blinded study of 80 patients diagnosed with idiopathic RBD.